BI-6015
Based on 5 publication(s) in Google Scholar
BI-6015 is a hepatocyte nuclear factor 4α (HNF4α) antagonist that can inhibit the expression of known HNF4α target genes. BI6015 represses insulin promoter activity through HNF4α antagonism. BI-6015 can be used for the research of cancer and diabetes.
For research use only. We do not sell to patients.
- Purity: 99.90%
- CAS No.: 93987-29-2
- Formula: C15H13N3O4S
- Molecular Weight:331.35
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
Publications Citing Use of MedChemExpress (MCE) BI-6015
More-
RT-PCR
-
Bio/Physico-chemical Assay
-
Cell Proliferation/Viability Assay
-
WB
-
IF
Biological Activity
hepatocyte nuclear factor 4α (HNF4α)[1]
BI-6015 (1.25-20 μM; 24-72 h) is cytotoxic to human hepatocellular carcinoma (HCC)[1].
BI-6015 (2.5-10 μM; 5-48 h) inhibits HNF4α gene expression in HepG2 cells[1].
BI-6015 (5 μM; 3 d) induces hepatic steatosis in primary murine hepatocytes[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Hep3B-Luc cells and primary hepatocytes
-
Concentration:1.25, 2.5, 5, 10, 20 μM
-
Incubation Time:24, 48, 72 hours
-
Result:Was markedly toxic to Hep3B cells but spared primary hepatocytes.
BI-6015 (10-30 mg/kg; i.p. daily or every other day for 20-57 days) induces apoptosis in a human hepatocellular carcinoma mouse model[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 93987-29-2
-
Appearance Solid
-
Molecular Weight 331.35
-
Formula C15H13N3O4S
-
Color White to off-white
-
SMILES
O=S(N1C2=CC=CC=C2N=C1C)(C3=CC([N+]([O-])=O)=CC=C3C)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (5)
-
Journal Impact Factor
-
Most Recent
-
Mol Syst Biol
Systemic genome-epigenome analysis captures a lineage-specific super-enhancer for MYB in gastrointestinal adenocarcinoma. [Abstract]2025 Apr 15. PMID: 40234694
BI-6015 purchased from MedChemExpress. Usage Cited in: Mol Syst Biol. 2025 Apr 15. [Abstract]
The expression of HNF4A and MYB upon the treatment of HNF4A antagonist BI-6015 (0-5 μM) in HT-55 cells.
BI-6015 purchased from MedChemExpress. Usage Cited in: Mol Syst Biol. 2025 Apr 15. [Abstract]
Luciferase reporter assay measuring the activity of theenhancer e4 following the treatment of HNF4A antagonist BI-6015 (0 and 5 μM) in HT-55 cells.
BI-6015 purchased from MedChemExpress. Usage Cited in: Mol Syst Biol. 2025 Apr 15. [Abstract]
Cell viability of HT-55 cells after 48 h treatment of BI-6015 (0-5 μM), measured by Cell Counting Kit-8 (CCK-8).
-
Int Immunopharmacol
Wogonoside ameliorates oxidative damage in tubular epithelial cells of diabetic nephropathy by modulating the HNF4A-NRF2 axis. [Abstract]2025 Apr 16:152:114481. PMID: 40086061 -
Elife
2024 Feb 20:13:e85985. PMID: 38375778
BI-6015 purchased from MedChemExpress. Usage Cited in: Elife. 2024 Feb 20:13:e85985. [Abstract]
Supplementation with colchicine (20 nM) significantly suppressed ACE2 levels in HPAEpiCs, which was reversed by treatment with BI6015 (20 μM) or siHNF4α.
BI-6015 purchased from MedChemExpress. Usage Cited in: Elife. 2024 Feb 20:13:e85985. [Abstract]
HPAEpiCs were treated with MithA (100 nM), BI6015 (20 μM), colchicine (20 nM), colchicine + MithA, or colchicine +BI6015, respectively. Representative images of immunofluorescence staining for ACE2 in HPAEpiCs.
-
-
Solvent & Solubility
DMSO : 50 mg/mL (150.90 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (282 KB)
-
SDS (392 KB)
- English - EN (392 KB)
- Français - FR (392 KB)
- Deutsch - DE (392 KB)
- Norwegian - NO (392 KB)
- Español - ES (392 KB)
- Swedish - SV (392 KB)
- Italian - IT (392 KB)
- Korean - KR (392 KB)
- Portuguese - PT (392 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.0180 mL | 15.0898 mL | 30.1796 mL | 75.4489 mL |
| 5 mM | 0.6036 mL | 3.0180 mL | 6.0359 mL | 15.0898 mL | |
| 10 mM | 0.3018 mL | 1.5090 mL | 3.0180 mL | 7.5449 mL | |
| 15 mM | 0.2012 mL | 1.0060 mL | 2.0120 mL | 5.0299 mL | |
| 20 mM | 0.1509 mL | 0.7545 mL | 1.5090 mL | 3.7724 mL | |
| 25 mM | 0.1207 mL | 0.6036 mL | 1.2072 mL | 3.0180 mL | |
| 30 mM | 0.1006 mL | 0.5030 mL | 1.0060 mL | 2.5150 mL | |
| 40 mM | 0.0754 mL | 0.3772 mL | 0.7545 mL | 1.8862 mL | |
| 50 mM | 0.0604 mL | 0.3018 mL | 0.6036 mL | 1.5090 mL | |
| 60 mM | 0.0503 mL | 0.2515 mL | 0.5030 mL | 1.2575 mL | |
| 80 mM | 0.0377 mL | 0.1886 mL | 0.3772 mL | 0.9431 mL | |
| 100 mM | 0.0302 mL | 0.1509 mL | 0.3018 mL | 0.7545 mL |